Literature DB >> 22252154

Patient heterogeneity and allocation bias: how should they be reported in clinical trials of chemotherapy for advanced gastric cancer?

Ichinosuke Hyodo.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22252154     DOI： 10.1007/s10120-011-0130-5

Source DB:  PubMed          Journal:  Gastric Cancer        ISSN： 1436-3291            Impact factor:   7.370


× No keyword cloud information.
  5 in total

1.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

Review 2.  Reporting patient characteristics and stratification factors in randomized trials of systemic chemotherapy for advanced gastric cancer.

Authors:  Kohei Shitara; Junko Ikeda; Chihiro Kondo; Daisuke Takahari; Takashi Ura; Kei Muro; Keitaro Matsuo
Journal:  Gastric Cancer       Date:  2011-08-13       Impact factor: 7.370

3.  Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.

Authors:  Atsushi Ohtsu; Manish A Shah; Eric Van Cutsem; Sun Young Rha; Akira Sawaki; Sook Ryun Park; Ho Yeong Lim; Yasuhide Yamada; Jian Wu; Bernd Langer; Michal Starnawski; Yoon-Koo Kang
Journal:  J Clin Oncol       Date:  2011-08-15       Impact factor: 44.544

4.  Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial.

Authors:  Jaffer A Ajani; Wuilbert Rodriguez; Gyorgy Bodoky; Vladimir Moiseyenko; Mikhail Lichinitser; Vera Gorbunova; Ihor Vynnychenko; August Garin; Istvan Lang; Silvia Falcon
Journal:  J Clin Oncol       Date:  2010-02-16       Impact factor: 44.544

5.  Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study.

Authors:  Narikazu Boku; Seiichiro Yamamoto; Haruhiko Fukuda; Kuniaki Shirao; Toshihiko Doi; Akira Sawaki; Wasaburo Koizumi; Hiroshi Saito; Kensei Yamaguchi; Hiroya Takiuchi; Junichiro Nasu; Atsushi Ohtsu
Journal:  Lancet Oncol       Date:  2009-10-07       Impact factor: 41.316
  5 in total
  1 in total

1.  Is serum HER2 ECD a predictive biomarker for response to trastuzumab in advanced gastric cancer?

Authors:  Takeshi Yamada; Yoshiyuki Yamamoto; Toshikazu Moriwaki; Ichisnosuke Hyodo
Journal:  J Gastroenterol       Date:  2016-02-18       Impact factor: 7.527
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.